AAN 2023 | Results of ocrelizumab in treatment-naïve patients with early relapsing MS

João José Cerqueira, MD, PhD, University of Minho, Braga, Portugal, describes the results of a subgroup analysis from the Phase III OPERA I/OPERA II (NCT01247324/NCT01412333) trials for the treatment of multiple sclerosis (MS) with first-line ocrelizumab (OCR). Selected patients had been diagnosed within two years and had no previous disease-modifying therapies. Patients were treated with OCR or interferon (IFN)-β-1a for a 96-week period. Patients then continued OCR treatment or switched to OCR from IFN for the open-label extension (OLE) of 9 years. Results showed that OCR patients had lower disease activity, disability progression, and relapses. OCR patients also had low levels of malignancies, serious infections, and adverse effects over the 9-year OLE. These results support the use of ocrelizumab as a first-line treatment in patients with early relapsing MS. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.